

Starting June 1, Blue Cross and BCN will cover only preferred hyaluronic acid products for GM, FCA and Ford commercial groups

Blue Cross Blue Shield of Michigan and Blue Care Network will cover select hyaluronic acid products under the medical benefit for General Motors, Fiat Chrysler Automobiles and Ford commercial groups starting June 1, 2021.

There are currently 16 hyaluronic acid products on the market that have been approved by the U.S. Food and Drug Administration. To date, no study has shown one hyaluronic acid product to be superior to another.

Starting June 1, we'll cover the following preferred hyaluronic acid products, which are listed on the left, for GM, FCA and Ford commercial groups.

Preferred (covered) hyaluronic acid products	Nonpreferred (noncovered) hyaluronic acid products
Durolane®	Gel-one®
Euflexxa®	GenVisc 850®
Gelsyn-3™	Hyalgan®
Supartz FX™	Hymovis®
	Monovisc®
	Orthovisc®
	Synvisc®
	Synvisc-One®
	TriVisc®
	Visco-3™
	Synjojoynt™
	Triluron™

Nonpreferred hyaluronic acid products, which will no longer be covered starting June 1, are listed on the right in the table above.

Here are some other things you need to know:

- Members receiving a nonpreferred hyaluronic acid product prior to June 1 can continue their treatment course until it is complete. However, effective June 1, we encourage providers to talk to their patients about using a preferred hyaluronic acid product for future treatment courses.

- Members who start hyaluronic acid therapy on or after June 1 will be required to use a preferred product.
- We'll notify affected members of these changes and encourage them to discuss treatment options with you.

Note: We started covering select hyaluronic acid products for other Blue Cross commercial and BCN commercial members on Jan. 1, 2020.